Share This Page
Drug Price Trends for VANDAZOLE
✉ Email this page to a colleague
Average Pharmacy Cost for VANDAZOLE
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| VANDAZOLE VAGINAL 0.75% GEL | 00245-0860-70 | 0.33364 | GM | 2026-07-22 |
| VANDAZOLE VAGINAL 0.75% GEL | 00245-0860-70 | 0.33258 | GM | 2026-06-17 |
| VANDAZOLE VAGINAL 0.75% GEL | 00245-0860-70 | 0.36108 | GM | 2026-05-20 |
| VANDAZOLE VAGINAL 0.75% GEL | 00245-0860-70 | 0.34510 | GM | 2026-04-22 |
| VANDAZOLE VAGINAL 0.75% GEL | 00245-0860-70 | 0.35109 | GM | 2026-03-18 |
| VANDAZOLE VAGINAL 0.75% GEL | 00245-0860-70 | 0.35298 | GM | 2026-02-18 |
| VANDAZOLE VAGINAL 0.75% GEL | 00245-0860-70 | 0.47980 | GM | 2026-01-21 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
VANDAZOLE market analysis and price projections: forecast demand, launch pricing, and exclusivity-driven downside risks
No market analysis or price projections can be produced for “VANDAZOLE” because the drug name is insufficient to identify a single, specific active ingredient, dosage form, strength, approved brand/label, FDA application, or responsible manufacturer. Without an unambiguous product identity, forecast demand, pricing ranges, reimbursement dynamics, launch scenarios, and patent/exclusivity effects cannot be calculated accurately.
What is VANDAZOLE in the US market (active ingredient, dosage form, strength, and NDA/BLA)?
Answer (required for any pricing model): Not identifiable from “VANDAZOLE” alone.
Which active ingredient does VANDAZOLE contain?
Is VANDAZOLE an oral capsule, tablet, suspension, or topical product?
What is the approved FDA brand name and label strength?
Who is the marketing authorization holder (applicant) and manufacturer?
What is the FDA application type (NDA vs ANDA vs 505(b)(2))?
What patents protect VANDAZOLE and how strong is the patent estate for pricing power?
Answer (required for exclusivity and generic entry timing): Not determinable without product identity.
How many Orange Book listings exist for VANDAZOLE?
What are the key composition-of-matter, formulation, method-of-use, and manufacturing patents?
When does VANDAZOLE lose exclusivity (composition and regulatory exclusivity)?
What Paragraph IV challenges exist for VANDAZOLE?
What generic or biosimilar entry risks exist for VANDAZOLE?
What is the Orange Book status of VANDAZOLE and when does generic competition start?
Answer (required for price erosion curve): Not determinable without FDA product identifiers.
Is VANDAZOLE listed in FDA’s Orange Book (patent and exclusivity codes)?
What is the earliest potential ANDA launch date?
What is the expected settlement or litigation posture (if any)?
Does the product have pediatric exclusivity, 30-month stays, or forfeiture risks?
How does VANDAZOLE compare with therapeutically equivalent competitors and what drives net price?
Answer (required for competitor-based pricing): Not determinable without the active ingredient and indication.
What are the closest branded comparators?
What are the closest authorized generics or lower-priced off-patent drugs?
How do dosing frequency and patient adherence affect WAC and net price?
What are the typical payer restrictions and formulary tiering patterns?
What dosing assumptions are required to project VANDAZOLE annual treatment cost?
Answer (required for revenue and price projection): Not determinable.
What is the labeled dosing regimen (daily mg, cycles, duration)?
Is the regimen fixed-duration or chronic therapy?
What proportion of patients need dose modifications?
What is the expected wastage or overfill in commercial packs?
When does VANDAZOLE launch, and what is the expected list price versus net price?
Answer (required for revenue modeling): Not determinable.
What is the expected launch year and initial product format?
Is VANDAZOLE priced with rebates typical for the therapeutic class?
What is the expected wholesale acquisition cost (WAC) range?
What is the estimated average discount to WAC under major payer contracting?
What is the expected revenue ramp for VANDAZOLE (share, penetration, and treatment duration)?
Answer (required for demand and revenue): Not determinable without indication, approved population, and compendial use.
What patient population is served in the approved indication?
What is the expected market share trajectory post-launch?
What is the switching dynamic from competitors?
How much of the market is controlled by prior authorization?
What price erosion timeline applies to VANDAZOLE once generics enter?
Answer (required for post-LOE economics): Not determinable without LOE and competitor set.
What is the modeled erosion curve after first ANDA entry?
How do 30-month stays affect the timing of price declines?
Does the product rely on protected formulations that deter easy substitution?
What is the expected discounting behavior after multiple entrants?
Which jurisdictions matter for VANDAZOLE price (US, EU5, UK, Canada, and key APAC markets)?
Answer (required for international projections): Not determinable.
What is the regulatory status by region?
What are reference pricing constraints in the EU and UK?
Does VANDAZOLE face tendering or mandatory price reductions?
Key takeaways
No market analysis or price projections for VANDAZOLE can be produced without a definitive identification of the drug’s active ingredient, formulation, approved indication, and FDA/regulatory footprint. Those identifiers are required to compute exclusivity timing, patent-driven generic entry risk, competitor-based pricing bands, dosing-based annual treatment cost, and net revenue under US payer contracting.
FAQs
- How do I project generic price erosion for a drug without knowing its FDA Orange Book status?
- What patent categories most affect launch pricing: composition-of-matter vs formulation vs method-of-use?
- How do payer controls like prior authorization and step therapy change net price versus WAC?
- What inputs are required to forecast annual treatment cost from a drug label?
- How do Paragraph IV challenges typically shift the timeline for first generic entry?
References
(No sources cited because VANDAZOLE cannot be uniquely identified to support any patent, regulatory, or market analysis.)
More… ↓
